SGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer

Molecular Cell

Volumn 56, Issue 4, 2014, Pages 595-607

  Gasser, Jessica A ^a   Inuzuka, Hiroyuki ^a   Lau, Alan W ^a   Wei, Wenyi ^a   Beroukhim, Rameen ^a,b,c,d   Toker, Alex ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE PHOSPHATASE; PROTEIN KINASE B; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; N-MYC DOWNSTREAM-REGULATED GENE 1 PROTEIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL-3,4-BISPHOSPHATE 4-PHOSPHATASE; PIK3CA PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SGK3 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; 3T3 CELL LINE; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CELL MOTION; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; GENETICS; HEK293 CELL LINE; METABOLISM; MOUSE; MUTATION; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; HEK293 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, NUDE; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NIH 3T3 CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PROTEOLYSIS; SIGNAL TRANSDUCTION;

EID: 84912100879     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2014.09.023     Document Type: Article

References (60)

1. Backer J.M. The regulation and function of class III PI3Ks: novel roles for Vps34. Biochem. J. 2008, 410:1-17.
2. Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 2011, 16(Suppl 1):12-19.
3. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
4. Buonamici S., Williams J., Morrissey M., Wang A., Guo R., Vattay A., Hsiao K., Yuan J., Green J., Ospina B., et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med. 2010, 2:51ra70.
5. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
6. Chan C.H., Li C.F., Yang W.L., Gao Y., Lee S.W., Feng Z., Huang H.Y., Tsai K.K., Flores L.G., Shao Y., et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 2012, 149:1098-1111.
7. Chin Y.R., Toker A. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell. Signal. 2009, 21:470-476.
8. Chin Y.R., Toker A. The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. Mol. Cell 2010, 38:333-344.
9. Choi Y., Zhang J., Murga C., Yu H., Koller E., Monia B.P., Gutkind J.S., Li W. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene 2002, 21:5289-5300.
10. Cleary J.M., Shapiro G.I. Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr. Oncol. Rep. 2010, 12:87-94.
11. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J.Clin. Oncol. 2010, 28:1075-1083.
12. Davids M.S., Brown J.R. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk. Lymphoma 2012, 53:2362-2370.
13. Debnath J., Brugge J.S. Modelling glandular epithelial cancers in three-dimensional cultures. Nat. Rev. Cancer 2005, 5:675-688.
14. Debnath J., Muthuswamy S.K., Brugge J.S. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268.
15. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7:606-619.
16. Fedele C.G., Ooms L.M., Ho M., Vieusseux J., O'Toole S.A., Millar E.K., Lopez-Knowles E., Sriratana A., Gurung R., Baglietto L., et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc. Natl. Acad. Sci. USA 2010, 107:22231-22236.
17. Firestone G.L., Giampaolo J.R., O'Keeffe B.A. Stimulus-dependent regulation of serum and glucocorticoid inducible protein kinase (SGK) transcription, subcellular localization and enzymatic activity. Cell. Physiol. Biochem. 2003, 13:1-12.
18. Franke T.F., Kaplan D.R., Cantley L.C., Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 1997, 275:665-668.
19. García-Martínez J.M., Alessi D.R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 2008, 416:375-385.
20. Gewinner C., Wang Z.C., Richardson A., Teruya-Feldstein J., Etemadmoghadam D., Bowtell D., Barretina J., Lin W.M., Rameh L., Salmena L., et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009, 16:115-125.
21. Harvell D.M., Richer J.K., Allred D.C., Sartorius C.A., Horwitz K.B. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinology 2006, 147:700-713.
22. Isakoff S.J., Engelman J.A., Irie H.Y., Luo J., Brachmann S.M., Pearline R.V., Cantley L.C., Brugge J.S. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005, 65:10992-11000.
23. Ivetac I., Gurung R., Hakim S., Horan K.A., Sheffield D.A., Binge L.C., Majerus P.W., Tiganis T., Mitchell C.A. Regulation of PI(3)K/Akt signalling and cellular transformation by inositol polyphosphate 4-phosphatase-1. EMBO Rep. 2009, 10:487-493.
24. Jaber N., Dou Z., Chen J.S., Catanzaro J., Jiang Y.P., Ballou L.M., Selinger E., Ouyang X., Lin R.Z., Zhang J., Zong W.X. Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function. Proc. Natl. Acad. Sci. USA 2012, 109:2003-2008.
25. Jamieson S., Flanagan J.U., Kolekar S., Buchanan C., Kendall J.D., Lee W.J., Rewcastle G.W., Denny W.A., Singh R., Dickson J., et al. A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem. J. 2011, 438:53-62.
26. Kachhap S.K., Faith D., Qian D.Z., Shabbeer S., Galloway N.L., Pili R., Denmeade S.R., DeMarzo A.M., Carducci M.A. The N-Myc down regulated gene1 (NDRG1) is a Rab4a effector involved in vesicular recycling of E-cadherin. PLoS ONE 2007, 2:e844.
27. Kapeller R., Toker A., Cantley L.C., Carpenter C.L. Phosphoinositide 3-kinase binds constitutively to α/β-tubulin and binds to γ-tubulin in response to insulin. J.Biol. Chem. 1995, 270:25985-25991.
28. Kobayashi T., Cohen P. Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. Biochem. J. 1999, 339:319-328.
29. Kobayashi T., Deak M., Morrice N., Cohen P. Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid-induced protein kinase. Biochem. J. 1999, 344:189-197.
30. Kovacevic Z., Richardson D.R. The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 2006, 27:2355-2366.
31. Lai C.L., Srivastava A., Pilling C., Chase A.R., Falke J.J., Voth G.A. Molecular mechanism of membrane binding of the GRP1 PH domain. J.Mol. Biol. 2013, 425:3073-3090.
32. Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J., Lee S.H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24:1477-1480.
33. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
34. Liu D., Yang X., Songyang Z. Identification ofcisK, a new member of the SGK kinase family that promotes IL-3-dependent survival. Curr. Biol. 2000, 10:1233-1236.
35. Luo J., Manning B.D., Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4:257-262.
36. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J.Biol. Chem. 1998, 273:13375-13378.
37. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
38. Mao J.H., Kim I.J., Wu D., Climent J., Kang H.C., DelRosario R., Balmain A. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008, 321:1499-1502.
39. Miao B., Skidan I., Yang J., Lugovskoy A., Reibarkh M., Long K., Brazell T., Durugkar K.A., Maki J., Ramana C.V., et al. Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc. Natl. Acad. Sci. USA 2010, 107:20126-20131.
40. Mora A., Komander D., van Aalten D.M., Alessi D.R. PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol. 2004, 15:161-170.
41. Murray J.T., Campbell D.G., Morrice N., Auld G.C., Shpiro N., Marquez R., Peggie M., Bain J., Bloomberg G.B., Grahammer F., et al. Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem. J. 2004, 384:477-488.
42. Najafov A., Sommer E.M., Axten J.M., Deyoung M.P., Alessi D.R. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem. J. 2011, 433:357-369.
43. Norris F.A., Majerus P.W. Hydrolysis of phosphatidylinositol 3,4-bisphosphate by inositol polyphosphate 4-phosphatase isolated by affinity elution chromatography. J.Biol. Chem. 1994, 269:8716-8720.
44. Norris F.A., Atkins R.C., Majerus P.W. The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type II. Evidence for conserved alternative splicing in the 4-phosphatase family. J.Biol. Chem. 1997, 272:23859-23864.
45. Pang H., Flinn R., Patsialou A., Wyckoff J., Roussos E.T., Wu H., Pozzuto M., Goswami S., Condeelis J.S., Bresnick A.R., et al. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res. 2009, 69:8868-8876.
46. Rajagopalan H., Jallepalli P.V., Rago C., Velculescu V.E., Kinzler K.W., Vogelstein B., Lengauer C. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004, 428:77-81.
47. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
48. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
49. Scheid M.P., Huber M., Damen J.E., Hughes M., Kang V., Neilsen P., Prestwich G.D., Krystal G., Duronio V. Phosphatidylinositol (3,4,5)P3 is essential but not sufficient for protein kinase B (PKB) activation; phosphatidylinositol (3,4)P2 is required for PKB phosphorylation at Ser-473: studies using cells from SH2-containing inositol-5-phosphatase knockout mice. J.Biol. Chem. 2002, 277:9027-9035.
50. Sherk A.B., Frigo D.E., Schnackenberg C.G., Bray J.D., Laping N.J., Trizna W., Hammond M., Patterson J.R., Thompson S.K., Kazmin D., et al. Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res. 2008, 68:7475-7483.
51. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98:10869-10874.
52. Stemke-Hale K., Gonzalez-Angulo A.M., Lluch A., Neve R.M., Kuo W.L., Davies M., Carey M., Hu Z., Guan Y., Sahin A., et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008, 68:6084-6091.
53. Tessier M., Woodgett J.R. Role of the phox homology domain and phosphorylation in activation of serum and glucocorticoid-regulated kinase-3. J.Biol. Chem. 2006, 281:23978-23989.
54. Tessier M., Woodgett J.R. Serum and glucocorticoid-regulated protein kinases: variations on a theme. J.Cell. Biochem. 2006, 98:1391-1407.
55. Vasudevan K.M., Barbie D.A., Davies M.A., Rabinovsky R., McNear C.J., Kim J.J., Hennessy B.T., Tseng H., Pochanard P., Kim S.Y., et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009, 16:21-32.
56. Wang Y., Zhou D., Phung S., Masri S., Smith D., Chen S. SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells. Mol. Endocrinol. 2011, 25:72-82.
57. Wang Z., Fukushima H., Gao D., Inuzuka H., Wan L., Lau A.W., Liu P., Wei W. The two faces of FBW7 in cancer drug resistance. BioEssays 2011, 33:851-859.
58. Woodgett J.R. Recent advances in the protein kinase B signaling pathway. Curr. Opin. Cell Biol. 2005, 17:150-157.
59. Xu J., Liu D., Gill G., Songyang Z. Regulation of cytokine-independent survival kinase (CISK) by the phox homology domain and phosphoinositides. J.Cell Biol. 2001, 154:699-705.
60. Xu J., Wan M., He Q., Bassett R.L., Fu X., Chen A.C., Shi F., Creighton C.J., Schiff R., Huo L., Liu D. SGK3 is associated with estrogen receptor expression in breast cancer. Breast Cancer Res. Treat. 2012, 134:531-541.